Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review

The new coronavirus disease 2019 (COVID-19) could be associated with elevated inflammatory cytokine levels, suggesting the involvement of cytokine release syndrome. This syndrome is characterized by release of interleukin 6 correlated with COVID-19 severity and mortality. Targeting IL-6 with Tociliz...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Geriatrics (Basel) 2022-02, Vol.7 (1), p.22
Hauptverfasser:	Ould Ouali, Cid, Ladjouzi, Nadia, Tamas, Khidher, Raveloson, Hendriniaina, Ben Hassen, Jihene, El Omeiri, Nesrine, Zouloumis, Georges, Al Zoabi, Mohamed Moataz, Asadi, Muneer, Jhouri, Aziza, Schlatter, Joël
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Blood pressure Case Report Case reports Clinical trials Coronaviruses COVID-19 Cytokine storm Drug dosages elderly Fever Heart rate Hemoglobin Hypertension Infections inflammatory syndrome Laboratories Monoclonal antibodies Mortality Older people Oxygen saturation Patients Pneumonia Severe acute respiratory syndrome coronavirus 2 Steroids Tocilizumab Tomography
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The new coronavirus disease 2019 (COVID-19) could be associated with elevated inflammatory cytokine levels, suggesting the involvement of cytokine release syndrome. This syndrome is characterized by release of interleukin 6 correlated with COVID-19 severity and mortality. Targeting IL-6 with Tocilizumab treatment could be a potential therapeutic option for old patients. We report the case of an 88-year-old man with COVID-19 disease who presented at the admission with anemia, fever, oxygen desaturation (92%), and inflammatory syndrome (C-reactive protein (CRP) at 182.5 mg/L; reference range
ISSN:	2308-3417 2308-3417
DOI:	10.3390/geriatrics7010022